A test developed by researchers at the University of Chicago has the potential to help physicians identify patients with the most lethal forms of triple-negative breast cancer, a disease that requires aggressive and innovative treatment.
Read MoreMolecular diagnostics company Biodesix announced that it has closed $8.4 million in Series E financing. The capital will help develop the company’s mass-spec technology platform and market the company’s first test, VeriStat, to guide NSCLC therapy.
Read MoreResearchers using the IsoFlux System have retrieved rare tumor cells from peripheral blood in early non-small cell lung cancer patients for molecular analysis. The study found that gross tumor volume positively correlated with CTC count.
Read More
Test accurately identifies which patients may need postsurgical chemotherapy.
Read More
Gene N. Herbek, MD, FCAP, was recently sworn in as president of the CAP, and Richard C. Friedberg, MD, PhD, FCAP, was sworn in as president-elect.
Read More